Literature DB >> 16427804

Evolution of a carbohydrate binding module into a protein-specific binder.

Lavinia Cicortas Gunnarsson1, Linda Dexlin, Eva Nordberg Karlsson, Olle Holst, Mats Ohlin.   

Abstract

A carbohydrate binding module, CBM4-2, derived from the xylanase (Xyn 10A) of Rhodothermus marinus has been used as a scaffold for molecular diversification. Its binding specificity has been evolved to recognise a quite different target, a human monoclonal IgG4. In order to understand the basis for this drastic change in specificity we have further investigated the target recognition of the IgG4-specific CBMs. Firstly, we defined that the structure target recognised by the selected CBM-variants was the protein and not the carbohydrates attached to the glycoprotein. We also identified key residues involved in the new specificity and/or responsible for the swap in specificity, from xylan to human IgG4. Specific changes present in all these CBMs included mutations not introduced in the design of the library from which the specific clones were selected. Reversion of such mutations led to a complete loss of binding to the target molecule, suggesting that they are critical for the recognition of human IgG4. Together with the mutations introduced at will, they had transformed the CBM scaffold into a protein binder. We have thus shown that the scaffold of CBM4-2 is able to harbour molecular recognition for either carbohydrate or protein structures.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16427804     DOI: 10.1016/j.bioeng.2005.12.002

Source DB:  PubMed          Journal:  Biomol Eng        ISSN: 1389-0344


  9 in total

1.  Comparison of the Biochemical Properties and Roles in the Xyloglucan-Rich Biomass Degradation of a GH74 Xyloglucanase and Its CBM-Deleted Variant from Thielavia terrestris.

Authors:  Beibei Wang; Kaixiang Chen; Peiyu Zhang; Liangkun Long; Shaojun Ding
Journal:  Int J Mol Sci       Date:  2022-05-09       Impact factor: 6.208

2.  Novel xylan-binding properties of an engineered family 4 carbohydrate-binding module.

Authors:  Lavinia Cicortas Gunnarsson; Cedric Montanier; Richard B Tunnicliffe; Mike P Williamson; Harry J Gilbert; Eva Nordberg Karlsson; Mats Ohlin
Journal:  Biochem J       Date:  2007-09-01       Impact factor: 3.857

Review 3.  Strategies and Tactics for the Development of Selective Glycan-Binding Proteins.

Authors:  Elizabeth M Ward; Megan E Kizer; Barbara Imperiali
Journal:  ACS Chem Biol       Date:  2021-01-26       Impact factor: 4.634

4.  Potential and utilization of thermophiles and thermostable enzymes in biorefining.

Authors:  Pernilla Turner; Gashaw Mamo; Eva Nordberg Karlsson
Journal:  Microb Cell Fact       Date:  2007-03-15       Impact factor: 5.328

5.  Selection of specific protein binders for pre-defined targets from an optimized library of artificial helicoidal repeat proteins (alphaRep).

Authors:  Asma Guellouz; Marie Valerio-Lepiniec; Agathe Urvoas; Anne Chevrel; Marc Graille; Zaineb Fourati-Kammoun; Michel Desmadril; Herman van Tilbeurgh; Philippe Minard
Journal:  PLoS One       Date:  2013-08-27       Impact factor: 3.240

Review 6.  Artificial affinity proteins as ligands of immunoglobulins.

Authors:  Barbara Mouratou; Ghislaine Béhar; Frédéric Pecorari
Journal:  Biomolecules       Date:  2015-01-30

7.  Characterization of the substitution pattern of cellulose derivatives using carbohydrate-binding modules.

Authors:  Laura von Schantz; Herje Schagerlöf; Eva Nordberg Karlsson; Mats Ohlin
Journal:  BMC Biotechnol       Date:  2014-12-24       Impact factor: 2.563

8.  Affinity maturation generates greatly improved xyloglucan-specific carbohydrate binding modules.

Authors:  Laura von Schantz; Fredrika Gullfot; Sebastian Scheer; Lada Filonova; Lavinia Cicortas Gunnarsson; James E Flint; Geoffrey Daniel; Eva Nordberg-Karlsson; Harry Brumer; Mats Ohlin
Journal:  BMC Biotechnol       Date:  2009-10-31       Impact factor: 2.563

Review 9.  The sweet and sour of serological glycoprotein tumor biomarker quantification.

Authors:  Uros Kuzmanov; Hari Kosanam; Eleftherios P Diamandis
Journal:  BMC Med       Date:  2013-02-07       Impact factor: 8.775

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.